Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients (UCMSC)
2021年11月23日 更新者:Bintang Soetjahjo, SpOT (K), MD. PhD、Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia
Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19
This study is conducted to assess the efficacy and safety of stem cells as adjunctive treatment for severe COVID-19 patients.
Here, we want to study whether the administration of mesenchymal stem cells are safe and able to relieve some of the COVID-19 symptoms
研究概览
详细说明
This is a randomized controlled trial.
double-blind, multi-center clinical study conducted at three different hospitals, on 21 patients who received intervention and 21 patients who received control treatment.
The purpose of this study is to evaluate the efficacy and safety of intravenous administration of normoxic allogeneic umbilical cord-derived mesenchymal stem cell (UCMSC) in the treatment group, compared to the control group who are only given standard COVID-19 treatments and normal saline infusion
研究类型
介入性
注册 (预期的)
42
阶段
- 阶段2
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Bintang Soetjahjo, MD PhD
- 电话号码:+628122987359
- 邮箱:bjortho@yahoo.com
学习地点
-
-
-
Yogyakarta、印度尼西亚、55281
- 招聘中
- Dr. Sardjito General Hospital
-
接触:
- Samekto Wibowo, Prof. MD
- 电话号码:+628122715617
-
首席研究员:
- Samekto Wibowo, Prof. MD
-
副研究员:
- Sumardi Sumardi, MD
-
副研究员:
- Sudadi Sudadi, MD, PhD
-
副研究员:
- Jarir At Thobari, MD, PhD
-
副研究员:
- E Henry Hamingtyas, MD, PhD
-
副研究员:
- Rusdy Ghazali Malueka, MD, PhD
-
-
Central Java
-
Surakarta、Central Java、印度尼西亚、57126
- 招聘中
- Dr. Moewardi General Hospital
-
接触:
- Arief Nurudhin, MD, PhD
- 电话号码:+6281393955596
-
首席研究员:
- Arief Nurudhin, MD, PhD
-
副研究员:
- Bintang Soetjahjo, MD. PhD
-
副研究员:
- Purwoko Purwoko, MD. PhD
-
副研究员:
- Artrian Adhiputri, MD
-
副研究员:
- Rina Sidharta, MD
-
副研究员:
- Widiastuti Widiastuti, MD, PhD
-
-
West Java
-
Bandung、West Java、印度尼西亚、40161
- 招聘中
- Dr. Hasan Sadikin
-
接触:
- Ahmad Faried, Prof. MD
- 电话号码:+6281320230371
-
首席研究员:
- Ahmad Faried, Prof. MD
-
副研究员:
- Rudi Wisaksana, MD. PhD
-
副研究员:
- Arto Yuwono, MD. PhD
-
副研究员:
- Tri Wahyu Murni, MD. PhD
-
副研究员:
- Reza Sudjud, MD. PhD
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Man or woman age 18-75 years
- SARS-CoV2 positive as confirmed by SARS-CoV2 RT-PCR Test
- Diagnosed with pnumonia as confirmed by chect radiography and history of fever, coug with one of the following symptoms: RR > 30x per minute, SaO2 93%, FaO2/FiO2 300 mmHg
- Voluntarily joined the clinical trial and has signed the informed consent form
Exclusion Criteria:
- Pregnant and lactating woman
- Patient who are diagnosed or have history of tumor and cancer
- Patient whose mother or sister are diagnosed with breast or ovarian cancer
- Level of SGPT/ALT is ≥ 5 times upper limit from normal value
- Level of eGFR is < 30 ml/min
- Reluctant to sign informed consent and unwilling to take the required tests
- Require invasive ventilation
- Shock
- Organ failure
- Currently involve in other clinical trial, or join another clinical trial in the last 3 months
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment
Group receiving standard COVID-19 treatment and UCMSC infusion
|
Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition, administered through intravenousinfusion at dose 1x10^6 cells MSC/kg body weight.
The treatment will be administered three times, at three days intervals (day 0, day 3, and day 6)
|
|
假比较器:Control
Group receiving standard COVID-19 treatment and normal saline infusion
|
Sterile saline solution and adminastered through intravenous infusion three times, at three day intervals (day 0, day 3, and day 6)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Duration of hospital stay
大体时间:20 - 24 days
|
Number of days since patient was administered until discharge in hospitals
|
20 - 24 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Post-administration clinical and radiological improvement
大体时间:Baseline/day-1 (-2 days), day-15 (+/- 2 days), day-22 (+/1 2 days) post randomization day
|
Chest X-ray evaluation; mMRC(Modified Medical Research Council) Dyspnea scale;
|
Baseline/day-1 (-2 days), day-15 (+/- 2 days), day-22 (+/1 2 days) post randomization day
|
|
Adverse Event and Serious Adverse Event Evaluation
大体时间:20 - 24 days
|
Evaluation of all adverse event or serious adverse event that is observed or reported by
|
20 - 24 days
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
合作者
调查人员
- 首席研究员:Arief Nurudin, MD PhD、Dr. Moewardi General Hospital, Surakarta, Indonesia
- 首席研究员:Samekto Wibowo, Prof. MD、Dr. Sardjito General Hospital, Yogyakarta, Indonesia
- 首席研究员:Ahmad Faried, Prof. MD、Dr. Hasan Sadikin General Hospital, Bandung, Indonesia
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. No abstract available. Erratum In: Lancet Respir Med. 2020 Feb 25;:
- Galipeau J, Sensebe L. Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell. 2018 Jun 1;22(6):824-833. doi: 10.1016/j.stem.2018.05.004.
- Atluri S, Manchikanti L, Hirsch JA. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Physician. 2020 Mar;23(2):E71-E83.
- Richardson JB. Urban forests near municipal solid waste incinerators do not show elevated trace metal or rare earth element concentrations across three cities in the northeast USA. Environ Sci Pollut Res Int. 2020 Jun;27(17):21790-21803. doi: 10.1007/s11356-020-08439-3. Epub 2020 Apr 12.
- Liang B, Chen J, Li T, Wu H, Yang W, Li Y, Li J, Yu C, Nie F, Ma Z, Yang M, Xiao M, Nie P, Gao Y, Qian C, Hu M. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore). 2020 Jul 31;99(31):e21429. doi: 10.1097/MD.0000000000021429.
- Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020 Jun 4;55(6):2000858. doi: 10.1183/13993003.00858-2020. Print 2020 Jun.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2021年1月17日
初级完成 (预期的)
2021年11月1日
研究完成 (预期的)
2021年11月1日
研究注册日期
首次提交
2021年11月23日
首先提交符合 QC 标准的
2021年11月23日
首次发布 (实际的)
2021年11月24日
研究记录更新
最后更新发布 (实际的)
2021年11月24日
上次提交的符合 QC 标准的更新
2021年11月23日
最后验证
2021年11月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.